Navigation Links
New drugs show promise for preventing 'absence seizures' in children: UBC research
Date:2/15/2012

A team led by a University of British Columbia professor has developed a new class of drugs that completely suppress absence seizures a brief, sudden loss of consciousness in rats, and which are now being tested in humans.

Absence seizures, also known as "petit mal seizures," are a symptom of epilepsy, most commonly experienced by children. During such episodes, the person looks awake but dazed. The seizures, arising from a flurry of high-frequency signals put out by the neurons of the thalamus, can be dangerous if they occur while a person is swimming or driving, and can also interrupt learning.

Available medications don't completely control such seizures in many patients. They also cause severe side effects, including sleepiness, blurred vision and diminished motor control.

A Canadian-Australian team, led by neuroscientist Terrance P. Snutch, a Canada Research Chair in the Michael Smith Laboratories at UBC, developed new drugs with a different target the flow of calcium into brain cells. Their findings were published today in Science Translational Medicine.

The new drugs, known as Z941 and Z944, block the flow of calcium ions into those neurons. When given to rats with absence epilepsy, they suppressed seizures by 85 to 90 per cent.

The team, which included collaborators at Zalicus Pharmaceuticals Ltd. of Vancouver and the University of Melbourne, was surprised to find that when seizures did occur, they were also of shorter duration; existing medications don't have any effect on the length of seizures.

The first phase of human clinical trials of Z944 began in December, with results expected later this year.

"Z941 and Z944 were designed to target a specific type of nerve cell calcium channel associated with epilepsy, as well as other hyper-excitability disorders such as chronic pain," says Snutch, a professor in the departments of psychiatry and zoology. "The dramatic effect of the drugs in rats with absence epilepsy, together with the drugs' ability to be administered orally and easily absorbed, and its good safety profile in animals, provide us with cautious optimism for the current clinical trial."


'/>"/>
Contact: Brian Kladko
brian.kladko@ubc.ca
604-827-3301
University of British Columbia
Source:Eurekalert

Related biology technology :

1. DFH Pharma to Collaborate With National Cancer Institute to Develop Second-Generation HIV Maturation Inhibitor Drugs
2. FDAs Oncologic Drugs Advisory Committee to Review Resubmitted Pixantrone New Drug Application on February 9, 2012
3. MarketsandMarkets: Lung Cancer Drugs Market in G7 Countries Worth $13 Billion by 2020
4. Malaria discovery gives hope for new drugs and vaccines
5. Permeon reveals discovery of Intraphilins as new approach to intracellular biologic drugs
6. Reportlinker Adds Innovations in Protein Kinase Therapies - Significant Proportion of Protein Kinase Pipeline Contains Small Molecule Drugs That Target Oncology
7. UCLA scientists discover new way to wake up the immune system using nano vaults to deliver drugs
8. Zacharon Pharmaceuticals Announces Research and Development Collaboration With Pfizer to Develop Drugs for Multiple Rare Disorders
9. Ontario Institute for Cancer Research Announces Investment in Microfluidics Technology for the Discovery of Anti-Cancer Drugs
10. Reportlinker Adds Biologic Therapeutic Drugs: Technologies and Global Markets
11. Isis Pharmaceuticals Adds Two New Drugs to Development Pipeline
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/9/2017)... Charlotte, N.C. (PRWEB) , ... October 09, 2017 , ... ... Purple announced Dr. Christopher Stubbs, a professor in Harvard University’s Departments of Physics and ... Dr. Stubbs was a member of the winning team for the 2015 Breakthrough Prize ...
(Date:10/7/2017)... Phoenix, Arizona (PRWEB) , ... ... ... than 15 years’ experience providing advanced instruments and applications consulting for microscopy ... the in-house expertise in application consulting, Nanoscience Analytical offers a broad range ...
(Date:10/6/2017)... ... 06, 2017 , ... The HealthTech Venture Network (HTVN) is ... fourth annual Conference where founders, investors, innovative practitioners and collaborators are invited to ... showcasing early stage digital health and med tech companies. , This day-long event ...
(Date:10/5/2017)... ... October 05, 2017 , ... Understanding the microbiome, the millions of bacteria ... Gut Love: You Are My Future, the newest exhibit on display at the University ... the human condition through the lens of the gut microbiome. , Gut Love ...
Breaking Biology Technology:
(Date:4/13/2017)... According to a new market research report "Consumer IAM Market ... Authorization), Service, Authentication Type, Deployment Mode, Vertical, and Region - Global Forecast ... from USD 14.30 Billion in 2017 to USD 31.75 Billion by 2022, ... ... MarketsandMarkets Logo ...
(Date:4/11/2017)... -- Research and Markets has announced the addition of ... offering. ... market to grow at a CAGR of 30.37% during the period ... has been prepared based on an in-depth market analysis with inputs ... growth prospects over the coming years. The report also includes a ...
(Date:4/11/2017)... April 11, 2017 NXT-ID, Inc. (NASDAQ: ... company, announces the appointment of independent Directors Mr. Robin ... its Board of Directors, furthering the company,s corporate governance and ... Gino Pereira ... look forward to their guidance and benefiting from their considerable ...
Breaking Biology News(10 mins):